| Medical and Health Sciences | Lifetime | 82 | KR 1 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 26 | KR 1 | 99.99 |
| Biological Sciences | 2021-2025 | 405 | KR 2 | 99.57 |
| Hematology | Lifetime | 6 | KR 1 | 99.97 |
| Oncology | Lifetime | 47 | KR 1 | 99.92 |
| Medical Genetics | Lifetime | 27 | KR 1 | 99.80 |
| Molecular Biology | Lifetime | 456 | KR 5 | 99.78 |
| Pathology and Forensic Medicine | Lifetime | 269 | KR 1 | 99.03 |
| Pulmonary and Respiratory Medicine | Lifetime | 843 | KR 13 | 98.66 |
| Reproductive Medicine | Lifetime | 562 | KR 2 | 95.51 |
| Infectious Diseases | Lifetime | 946 | KR 5 | 95.18 |
| Obstetrics and Gynecology | Lifetime | 714 | KR 3 | 91.03 |
| Hematology | 2021-2025 | 3 | KR 1 | 99.95 |
| Molecular Biology | 2021-2025 | 69 | KR 2 | 99.73 |
| Oncology | 2021-2025 | 64 | KR 3 | 99.65 |
| Medical Genetics | 2021-2025 | 33 | KR 1 | 99.26 |
| Infectious Diseases | 2021-2025 | 107 | KR 1 | 98.31 |
| Pathology and Forensic Medicine | 2021-2025 | 246 | KR 6 | 92.71 |
| Clinical Neurology | 2021-2025 | 563 | KR 8 | 76.28 |
| Cancer Research | 2021-2025 | 399 | KR 6 | 71.50 |
| Peptidase Inhibition and Analysis | Lifetime | 3 | KR 1 | 99.97 |
| Cancer Treatment and Pharmacology | Lifetime | 4 | KR 1 | 99.97 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 9 | KR 1 | 99.92 |
| Multiple Myeloma Research and Treatments | Lifetime | 5 | KR 1 | 99.97 |
| Protein Degradation and Inhibitors | Lifetime | 4 | KR 1 | 99.95 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 10 | KR 1 | 99.79 |
| Lymphoma Diagnosis and Treatment | Lifetime | 43 | KR 1 | 99.80 |
| Cancer Mechanisms and Therapy | Lifetime | 18 | KR 1 | 99.53 |
| COVID-19 Clinical Research Studies | Lifetime | 103 | KR 1 | 99.36 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 31 | KR 1 | 99.63 |
| Bone health and treatments | Lifetime | 61 | KR 1 | 99.62 |
| Cancer therapeutics and mechanisms | Lifetime | 62 | KR 1 | 99.48 |
| Ubiquitin and proteasome pathways | Lifetime | 87 | KR 1 | 99.46 |
| Histone Deacetylase Inhibitors Research | Lifetime | 69 | KR 1 | 99.21 |
| Long-Term Effects of COVID-19 | Lifetime | 143 | KR 2 | 98.50 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 151 | KR 2 | 99.14 |
| Ovarian cancer diagnosis and treatment | Lifetime | 189 | KR 2 | 99.04 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 217 | KR 1 | 98.85 |
| Hematological disorders and diagnostics | Lifetime | 86 | KR 1 | 98.50 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 480 | KR 7 | 98.39 |
| Bone and Joint Diseases | Lifetime | 147 | KR 1 | 98.64 |
| Multiple and Secondary Primary Cancers | Lifetime | 161 | KR 3 | 98.08 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 386 | KR 8 | 98.41 |
| Viral-associated cancers and disorders | Lifetime | 389 | KR 4 | 97.87 |
| Neuroendocrine Tumor Research Advances | Lifetime | 660 | KR 10 | 97.88 |
| Testicular diseases and treatments | Lifetime | 222 | KR 3 | 97.38 |
| Renal cell carcinoma treatment | Lifetime | 603 | KR 11 | 97.58 |
| COVID-19 and healthcare impacts | Lifetime | 581 | KR 5 | 94.07 |
| Urinary and Genital Oncology Studies | Lifetime | 365 | KR 8 | 97.53 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 253 | KR 5 | 96.75 |
| Endometrial and Cervical Cancer Treatments | Lifetime | 667 | KR 23 | 97.01 |
| Lung Cancer Research Studies | Lifetime | 950 | KR 27 | 96.97 |
| Advanced Breast Cancer Therapies | Lifetime | 555 | KR 12 | 95.70 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 330 | KR 1 | 93.79 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 848 | KR 12 | 94.11 |
| Neutropenia and Cancer Infections | Lifetime | 690 | KR 3 | 94.68 |
| SARS-CoV-2 detection and testing | Lifetime | 842 | KR 23 | 90.44 |
| Chemotherapy-related skin toxicity | Lifetime | 327 | KR 1 | 90.23 |
| Dermatological and Skeletal Disorders | Lifetime | 741 | KR 4 | 88.26 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 935 | KR 4 | 85.71 |
| Osteomyelitis and Bone Disorders Research | Lifetime | 416 | KR 6 | 80.25 |
| Male Breast Health Studies | Lifetime | 859 | KR 7 | 55.63 |
| Beetle Biology and Toxicology Studies | Lifetime | 654 | KR 2 | 52.92 |
| Peptidase Inhibition and Analysis | 2021-2025 | 1 | KR 1 | 99.94 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 2 | KR 1 | 99.97 |
| Protein Degradation and Inhibitors | 2021-2025 | 2 | KR 1 | 99.94 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 12 | KR 1 | 99.77 |
| COVID-19 Clinical Research Studies | 2021-2025 | 150 | KR 1 | 99.15 |
| Cancer Mechanisms and Therapy | 2021-2025 | 12 | KR 1 | 98.46 |
| Cancer Treatment and Pharmacology | 2021-2025 | 37 | KR 4 | 99.24 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 298 | KR 3 | 98.71 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 25 | KR 1 | 98.90 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 110 | KR 3 | 98.84 |
| Ubiquitin and proteasome pathways | 2021-2025 | 56 | KR 1 | 96.64 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 216 | KR 4 | 96.02 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 114 | KR 2 | 97.88 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 133 | KR 1 | 96.34 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 174 | KR 2 | 95.62 |
| HIV/AIDS drug development and treatment | 2021-2025 | 192 | KR 1 | 94.01 |
| SARS-CoV-2 detection and testing | 2021-2025 | 494 | KR 10 | 91.72 |
| Advanced Breast Cancer Therapies | 2021-2025 | 425 | KR 11 | 92.08 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 711 | KR 31 | 90.79 |
| Animal Virus Infections Studies | 2021-2025 | 714 | KR 14 | 87.44 |
| Cancer therapeutics and mechanisms | 2021-2025 | 300 | KR 6 | 85.67 |
| HER2/EGFR in Cancer Research | 2021-2025 | 866 | KR 37 | 86.36 |
| PARP inhibition in cancer therapy | 2021-2025 | 667 | KR 17 | 83.35 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 398 | KR 6 | 80.90 |
| Bone health and treatments | 2021-2025 | 553 | KR 29 | 79.65 |
| Parathyroid Disorders and Treatments | 2021-2025 | 837 | KR 20 | 80.46 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 441 | KR 14 | 69.49 |
| Hematological disorders and diagnostics | 2021-2025 | 410 | KR 5 | 66.95 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 687 | KR 14 | 65.22 |
| Chemokine receptors and signaling | 2021-2025 | 492 | KR 13 | 62.41 |
| Dermatological and Skeletal Disorders | 2021-2025 | 821 | KR 1 | 40.43 |
| Natural Product Synthesis and Anticancer Bioactivity | 2021-2025 | 220 | KR 2 | 32.65 |
| Beetle Biology and Toxicology Studies | 2021-2025 | 143 | KR 1 | 14.07 |
